Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials

The New York Times - Business:

Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.

Author: Pam Belluck

This post first appeared in The New York Times - Business. Read the original article.